Correlates for completion of 3-dose regimen of HPV vaccine in female members of a managed care organization

Mayo Clinic Proceedings

Volumn 84, Issue 10, 2009, Pages 864-870

  Chun, Chao ^a   Velicer, Christine ^b   Slezak, Jeff M ^a   Jacobsen, Steven J ^a  

^a KAISER PERMANENTE   (United States)

^b MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

WART VIRUS VACCINE;

ADOLESCENT; ADULT; ARTICLE; CHILD; DRUG EFFICACY; ETHNICITY; FEMALE; GROUPS BY AGE; HEALTH CARE ORGANIZATION; HEALTH INSURANCE; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 4; IMMUNE RESPONSE; MAJOR CLINICAL STUDY; SCHOOL CHILD; VERRUCA VULGARIS;

EID: 70350215767     PISSN: 00256196     EISSN: None     Source Type: Journal    
DOI: 10.4065/84.10.864     Document Type: Article

References (11)

1. Villa LL, Costa RL, Petta CA, et al. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol. 2005;6(5):271-278. (Pubitemid 40590263)
2. Villa LL, Costa RL, Petta CA, et al. High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up. Br J Cancer. 2006 Dec 4;95(11): 1459-1466. Epub 2006 Nov 21.
3. Markowitz LE, Dunne EF, Saraiya M, Lawson HW, Chesson H, Unger ER. Quadrivalent human papillomavirus vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2007;56(RR-2):1-24.
4. Department of Health and Human Services, Centers for Disease Control and Prevention.Vaccination coverage among adolescents aged 13-17 years - United States, 2007 [published correction appears in MMWR Morb Mortal Wkly Rep. 2009;58(1):10]. MMWR Morb Mortal Wkly Rep. 2008;57(40): 1100-1103.
5. Sellors J, Pickard L, Mahony JB, et al. Understanding and enhancing compliance with the second dose of hepatitis B vaccine: a cohort analysis and a randomized controlled trial. CMAJ. 1997;157(2):143-148. (Pubitemid 27348219)
6. Chen W, Petitti DB, Enger S. Limitations and potential uses of census-based data on ethnicity in a diverse community. Ann Epidemiol. 2004;14(5): 339-345. (Pubitemid 38737327)
7. U.S. Preventive Services Task Force. Screening for cervical cancer: recommendations and rationale. Am Fam Physician. 2003;67(8):1759-1766.
8. Liu T, Wang X, Waterbor JW, Weiss HL, Soong SJ. Relationships between socioeconomic status and race-specific cervical cancer incidence in the United States, 1973-1992. J Health Care Poor Underserved. 1998;9(4):420-432.
9. McDougall JA, Madeleine MM, Daling JR, Li CI. Racial and ethnic disparities in cervical cancer incidence rates in the United States, 1992-2003. Cancer Causes Control. 2007 Dec;18(10):1175-1186. Epub 2007 Sep 6.
10. Riedesel JM, Rosenthal SL, Zimet GD, et al. Attitudes about human papillomavirus vaccine among family physicians. J Pediatr Adolesc Gynecol. 2005;18(6):391-398. (Pubitemid 41773995)
11. Kiefe CI, Funkhouser E, Fouad MN, May DS. Chronic disease as a barrier to breast and cervical cancer screening. J Gen Intern Med. 1998;13(6): 357-365. (Pubitemid 28294713)